Quality & Compliance: Preparing for Health Authority Interactions and Advisory Committees

| 01 February 2009

Many mainstream and trade journalists have recently noted that the US Food and Drug Administration (FDA) has become more cautious and sometimes harsh in its reviews of drug/biologic/medical device safety and efficacy data. Because of this, professionalism in the presentation of data and responses to challenging division staff and advisory committee questions has become critically important.


© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy